<DOC>
	<DOCNO>NCT01290965</DOCNO>
	<brief_summary>This study examine effectiveness 15 day therapy SCY-635 reduce hepatitis C virus ( HCV ) RNA level .</brief_summary>
	<brief_title>Safety , PK Efficacy 15 Days SCY-635 Treatment Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>A potential subject eligible participation study meet follow inclusion criterion : The subject either male female , age 18 65 year ( inclusive ) . The subject read sign Subject Informed Consent form participate study . If subject fluent English , Subject Informed Consent form must translate native language . Female subject childbearing potential ( i.e. , woman surgically sterile least two year postmenopausal ) must agree utilize one follow form contraception Screening completion study : abstinence , barrier ( condom , diaphragm spermicide ) , intrauterine device ( IUD ) , vasectomized partner ( six month minimum ) . Hormonal contraception ( oral , transdermal , implant , injection ) permit study period ( i.e. , Screening Followup visit ) . Note : For woman age &lt; 50 year , postmenopausal define least two year cessation menses . For woman age â‰¥50 year , postmenopausal define least one year cessation menses . Estrogen replacement allow study . The subject exhibit quantifiable plasma level HCVspecific RNA excess 100,000 IU/mL determine quantitative Roche COBAS taqMan assay . The subject negative urine screen amphetamine , barbiturate , cocaine , opiates , phencyclidine Screening . If female , subject negative serum pregnancy test Screening ( within 30 day prior dose ) negative urine pregnancy test Study Day 1 . A potential subject exclude participation study meet follow exclusion criterion : The subject history clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease , condition , opinion Principal Investigator , may jeopardize safety subject may impact validity study result . The subject infect HCV genotype genotype 1 . The subject document positive antibody test Human Immunodeficiency Virus Types 1 2 ( p24 antibody specific HIV1 HIV2 ) Hepatitis B virus ( HBV ) surface antigen ( HbSAg ) Screening exhibit serologic evidence infection either HIV1 , HIV2 HBV . The subject donate blood within 30 day prior dose donate plasma within 14 day prior dose . The subject use investigational agent within three month prior dose . The subject receive FDAapproved antiHCV therapy ( include ribavirin product contain interferon ) within three month prior dose . The subject exhibit evidence decompensated liver disease , mark bilirubin great 4 mg/dL , albumin less 3.0 g/dL , prothrombin time great 2 second prolonged , history bleed esophageal varix , ascites hepatic encephalopathy . The subject organ transplant recipient . The subject exhibit ALT value great equal 2.5 time upper limit normal . The subject exhibit evidence hepatocellular carcinoma either exhibit serum alphafetoprotein concentration exceed 50 mg/L exhibit mass suggestive liver cancer ultrasound image technology . The subject exhibit evidence ongoing alcohol substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>